Generated by All in One SEO v4.9.7.1, this is an llms.txt file, used by LLMs to index the site. # AIMS-2-TRIALS - Autism Research For Europe AIMS-2-TRIALS - Autism Research For Europe ## Posts - [Longitudinal European Autism Project: Summary Of Key Achievements](https://www.aims-2-trials.eu/2026/07/10/longitudinal-european-autism-project-summary-of-key-achievements/) - [AIMS-2-TRIALS A-Rep Dr Mary Doherty honoured with British Citizen Award](https://www.aims-2-trials.eu/2026/07/03/aims-2-trials-a-rep-dr-mary-doherty-honoured-with-british-citizen-award/) - [AIMS-2-TRIALS Dataset Made Available Through Managed Access Following Community Collaboration](https://www.aims-2-trials.eu/2026/06/22/aims-2-trials-dataset-made-available-through-managed-access-following-community-collaboration/) - [Autistic people’s priorities for change across Europe](https://www.aims-2-trials.eu/2026/03/18/autistic-peoples-priorities-for-change-across-europe/) - [Roche and AIMS-2-TRIALS Receives EURORDIS Black Pearl Award 2026](https://www.aims-2-trials.eu/2026/03/10/roche-and-aims-2-trials-receives-eurordis-black-pearl-award-2026/) - [Early Career Researcher? Join ECRAN](https://www.aims-2-trials.eu/2021/05/10/early-career-reseracher-join-ecran/) - [Researcher training opportunities](https://www.aims-2-trials.eu/2020/08/06/researcher-training-opportunities-3/) - [Towards a common approach for autism in Europe – European Parliamentary Event](https://www.aims-2-trials.eu/2025/05/21/towards-a-common-approach-for-autism-in-europe-european-parliamentary-event/) - [Art & Science Competition and Exhibition](https://www.aims-2-trials.eu/2024/02/05/more-than-meets-the-eye-art-competition/) - [What can we learn about autism in adults from the eye?](https://www.aims-2-trials.eu/2024/05/31/what-can-we-learn-about-autism-in-adults-from-the-eye/) - [Autism Without Boarders Award Event 2023](https://www.aims-2-trials.eu/2024/02/15/autism-without-borders-award-event-2023/) - [New Project: European Autism Genomics Registry](https://www.aims-2-trials.eu/2023/08/02/new-project-european-autism-genomics-registry/) - [Bridging the gap: AIMS-2-TRIALS collaborators advocate for neurodiversity-affirming research](https://www.aims-2-trials.eu/2023/10/18/bridging-the-gap-aims-2-trials-collaborators-advocate-for-neurodiversity-affirming-research/) - [The Value of Treatment](https://www.aims-2-trials.eu/2022/05/31/the-value-of-treatment/) - [AIMS-2-TRIALS is in the 'Top 10' IMI Projects](https://www.aims-2-trials.eu/2023/08/24/aims-2-trials-is-in-the-top-10-imi-projects-2/) - [Studying male and female brains: do they differ between autistic and non-autistic people?](https://www.aims-2-trials.eu/2023/07/11/studying-male-and-female-brains-do-they-differ-between-autistic-and-non-autistic-people/) - [AIMS-2-TRIALS consultation on data sharing](https://www.aims-2-trials.eu/2023/05/03/aims-2-trials-consultation-on-data-sharing/) - [Autistic people may pay less attention to faces due to the way their brains process sensory information](https://www.aims-2-trials.eu/2023/04/20/autistic-people-may-pay-less-attention-to-faces-due-to-the-way-their-brains-process-sensory-information/) - [Understanding autism: Linking genetics, brain structure and behaviour](https://www.aims-2-trials.eu/2023/03/29/understanding-autism-linking-genetics-brain-structure-and-behaviour/) - [AIMS-2-TRIALS Work Package Updates for 2022](https://www.aims-2-trials.eu/2022/12/14/work-package-updates-for-2022/) - [Recognising faces: microstates](https://www.aims-2-trials.eu/2022/12/19/recognising-faces-microstates/) - [Measuring brain activity may help tailor support for autistic people](https://www.aims-2-trials.eu/2022/12/19/measuring-brain-activity-may-help-tailor-support-for-autistic-people/) - [Reviewing the evidence for medications and dietary supplements to support autistic people](https://www.aims-2-trials.eu/2022/06/20/reviewing-the-evidence-for-medications-and-dietary-supplements-to-support-autistic-people/) - [Exploring the brain biology of people with rare genetic conditions related to autism](https://www.aims-2-trials.eu/2022/06/13/exploring-the-brain-biology-of-people-with-rare-genetic-conditions-related-to-autism-2/) - [Exploring the brain biology of people with rare genetic conditions related to autism](https://www.aims-2-trials.eu/2022/06/10/exploring-the-brain-biology-of-people-with-rare-genetic-conditions-related-to-autism/) - [INSAR (International Society for Autism Research): May 2022](https://www.aims-2-trials.eu/2022/05/19/insar-international-society-for-autism-research-may-2022/) - [Variation in brain structure is linked to changes in adaptive behaviour in autistic people](https://www.aims-2-trials.eu/2022/05/19/variation-in-brain-structure-is-linked-to-changes-in-adaptive-behaviour-in-autistic-people-2/) - [Variation in brain structure is linked to changes in adaptive behaviour in autistic people](https://www.aims-2-trials.eu/2022/04/29/variation-in-brain-structure-is-linked-to-changes-in-adaptive-behaviour-in-autistic-people/) - [AIMS-2-TRIALS Partners involved in Lancet Commission](https://www.aims-2-trials.eu/2022/04/19/aims-2-trials-partners-involved-in-lancet-commission-2/) - [Attention in infants is linked to differences in biological sex and socio-economic status](https://www.aims-2-trials.eu/2022/04/19/attention-in-infants-is-linked-to-differences-in-biological-sex-and-socio-economic-status-2/) - [Closer collaborations needed between scientists and the autistic community](https://www.aims-2-trials.eu/2022/04/19/closer-collaborations-needed-between-scientists-and-the-autistic-community-2/) - [Infants' brain activity when seeing faces is written in their DNA](https://www.aims-2-trials.eu/2022/04/19/infants-brain-activity-when-seeing-faces-is-written-in-their-dna-2/) - [Developing wearable technology with involvement from autistic people](https://www.aims-2-trials.eu/2022/04/19/developing-wearable-technology-with-involvement-from-autistic-people-2/) - [AIMS-2-TRIALS innovations are among those selected for EU Innovation Radar Platform](https://www.aims-2-trials.eu/2022/04/19/aims-2-trials-innovations-are-among-those-selected-for-eu-innovation-radar-platform-2/) - [Closer collaborations needed between scientists and the autistic community](https://www.aims-2-trials.eu/2021/11/16/closer-collaborations-needed-between-scientists-and-the-autistic-community/) - [AIMS-2-TRIALS Partners involved in Lancet Commission](https://www.aims-2-trials.eu/2022/01/27/aims-2-trials-partners-involved-in-lancet-commission/) - [Attention in infants is linked to differences in biological sex and socio-economic status](https://www.aims-2-trials.eu/2021/12/14/attention-in-infants-is-linked-to-differences-in-biological-sex-and-socio-economic-status/) - [Infants' brain activity when seeing faces is written in their DNA](https://www.aims-2-trials.eu/2021/07/05/infants-brain-activity-when-seeing-faces-is-written-in-their-dna/) - [Impatto economico del percorso diagnostico e intervento precoce in bambini/ adolescenti con autismo](https://www.aims-2-trials.eu/2021/08/02/impatto-economico-del-percorso-diagnostico-e-intervento-precoce-in-bambini-con-autismo/) - [Estudio del diagnóstico de cribado e intervención temprana en niños con autismo](https://www.aims-2-trials.eu/2021/04/27/estudio-del-diagnostico-de-cribado-e-intervencion-temprana-en-ninos-con-autismo/) - [Developing wearable technology with involvement from autistic people](https://www.aims-2-trials.eu/2021/07/01/developing-wearable-technology-with-involvement-from-autistic-people/) - [European Society of Child and Adolescent Psychiatry endorses AIMS-2-TRIALS partner publication](https://www.aims-2-trials.eu/2020/09/16/escap/) - [AIMS-2-TRIALS innovations are among those selected for EU Innovation Radar Platform](https://www.aims-2-trials.eu/2021/06/28/aims-2-trials-innovations-are-among-those-selected-for-eu-innovation-radar-platform/) - [AIMS-2-TRIALS research into autism subtypes at Birkbeck](https://www.aims-2-trials.eu/2021/03/03/aims-2-trials-research-into-autism-subtypes-at-birkbeck/) - [VIDEO: AIMS-2-TRIALS research into autism subtypes at Birkbeck](https://www.aims-2-trials.eu/2021/05/26/aims-2-trials-research-into-autism-subtypes-at-birkbeck-3/) - [What services do autistic people want? What improvements are needed? Let policymakers know.](https://www.aims-2-trials.eu/2021/05/25/what-services-do-autistic-people-want-what-improvements-are-needed-time-to-let-policymakers-know-2/) - [INSAR (International Society for Autism Research): 3-7 May 2021](https://www.aims-2-trials.eu/2021/06/07/insar/) - [New AIMS-2-TRIALS database developed by Institut Pasteur](https://www.aims-2-trials.eu/2021/05/09/new-aims-2-trials-database-developed-by-institut-pasteur/) - [Understanding placebo response in clinical trials with autistic people](https://www.aims-2-trials.eu/2021/05/10/understanding-placebo-response-in-clinical-trials-with-autistic-people/) - [How quality of life is influenced by depression and anxiety in autism](https://www.aims-2-trials.eu/2021/05/10/how-quality-of-life-is-influenced-by-depression-and-anxiety-in-autism/) - [Are there differences in the brains of autistic men and women?](https://www.aims-2-trials.eu/2021/05/10/are-there-differences-in-the-brains-of-autistic-men-and-women-2/) - [Cellular memory of mother's viral infection could play a role in child's later brain development](https://www.aims-2-trials.eu/2021/05/10/cellular-memory-of-mothers-viral-infection-could-play-a-role-in-childs-later-brain-development-2/) - [New white paper published on a framework for drug discovery in autism](https://www.aims-2-trials.eu/2021/05/22/whitepaper/) - [Distinct behavioural profiles of autism matter](https://www.aims-2-trials.eu/2021/05/26/distinct-behavioural-profiles-of-autism-matter-2/) - [Attentive brain states to faces in infants with and without later autism](https://www.aims-2-trials.eu/2021/05/26/attentive-brain-states-to-faces-in-infants-with-and-without-later-autism/) - [ECNP Congress: 2-5 October 2021](https://www.aims-2-trials.eu/2021/06/07/ecnp-congress/) - [OHBM (Organisation for Human Brain Mapping): 21-25 June 2021](https://www.aims-2-trials.eu/2021/06/07/ohbm-2021/) - [EACD (European Academy of Childhood Disability): 20 May 2021](https://www.aims-2-trials.eu/2021/06/07/eacd-european-academy-of-childhood-disability-20-may-2021/) - [Professors Emily Jones and Tony Charman are guests on the PsychologiCall Podcast](https://www.aims-2-trials.eu/2021/05/10/professor-emily-jones-on-psychologicall-podcast-2/) - [COVID exacerbates healthcare inequalities for autistic people](https://www.aims-2-trials.eu/2021/05/26/covid-exacerbates-healthcare-inequalities-for-autistic-people/) - [Society for Neuroscience (SfN) 50th Annual Meeting: 13-17 November 2021](https://www.aims-2-trials.eu/2021/05/10/sfn-2021/) - [British Association for Psychopharmacology Summer Meeting: 19-21 July 2021](https://www.aims-2-trials.eu/2021/06/07/british-association-for-psychopharmacology-2021-summer-meeting/) - [WAIMH (World Association for Infant Mental Health): 22-26 June 2021](https://www.aims-2-trials.eu/2021/06/07/waimh-2021/) - [Annual Meeting of the Spanish Association for Child and Adolescent Psychiatry: 3-4 June 2021](https://www.aims-2-trials.eu/2021/06/07/spanish-association-for-child-and-adolescent-psychiatry/) - [German TV documentary: Autismus - Eine Welt für sich? (Autism: A world of its own?)](https://www.aims-2-trials.eu/2021/02/07/german-tv-documentary-autismus-eine-welt-fur-sich-autism-a-world-of-its-own/) - [Reviewing healthcare barriers for autistic people](https://www.aims-2-trials.eu/2021/05/26/reviewing-healthcare-barriers-for-autistic-people-2/) - [European Society of Child and Adolescent Psychiatry endorses AIMS-2-TRIALS partner publication](https://www.aims-2-trials.eu/2021/05/12/european-society-of-child-and-adolescent-psychiatry-endorses-aims-2-trials-partner-publication/) - [AIMS-2-TRIALS colleagues feature on highly-cited researchers list](https://www.aims-2-trials.eu/2021/05/26/cited-researchers/) - [Reviewing healthcare barriers for autistic people](https://www.aims-2-trials.eu/2021/05/19/reviewing-healthcare-barriers-for-autistic-people/) - [UPDATE: Favourable feedback from European Medicines Agency](https://www.aims-2-trials.eu/2021/05/22/update-favourable-feedback-from-european-medicines-agency-2/) - [What do AIMS-2-TRIALS Autism Representatives (A-Reps) do?](https://www.aims-2-trials.eu/2021/05/22/what-do-aims-2-trials-autism-representatives-a-reps-do/) - [New AIMS-2-TRIALS database developed by Institut Pasteur](https://www.aims-2-trials.eu/2021/01/19/new-database-developed-for-aims-2-trials-by-institut-pasteur/) - [Attentive brain states to faces in infants with and without later autism](https://www.aims-2-trials.eu/2021/04/12/attentivebrainstates/) - [COVID exacerbates healthcare inequalities for autistic people](https://www.aims-2-trials.eu/2021/05/18/covid-2/) - [Distinct behavioural profiles of autism matter](https://www.aims-2-trials.eu/2021/05/17/distinct-behavioural-profiles-of-autism-matter/) - [New AIMS-2-TRIALS research on social behaviour in the mouse and what it can tell us about autism](https://www.aims-2-trials.eu/2021/05/10/new-aims-2-trials-research-on-social-behaviour-in-the-mouse-and-what-it-can-tell-us-about-autism/) - [Autistic people focus on social information differently to non-autistic people](https://www.aims-2-trials.eu/2021/05/10/autistic-people-focus-on-social-information-differently-to-non-autistic-people-2/) - [Understanding placebo response in clinical trials with autistic people](https://www.aims-2-trials.eu/2020/10/14/placebo-response/) - [How quality of life is influenced by depression and anxiety in autism](https://www.aims-2-trials.eu/2020/10/07/quality_of_life/) - [Are there differences in the brains of autistic men and women?](https://www.aims-2-trials.eu/2021/03/10/are-there-differences-in-the-brains-of-autistic-men-and-women/) - [Autistic people focus on social information differently to non-autistic people](https://www.aims-2-trials.eu/2020/12/08/autistic-people-focus-on-social-information-differently-to-non-autistic-people/) - [New AIMS-2-TRIALS research on social behaviour in the mouse and what it can tell us about autism](https://www.aims-2-trials.eu/2021/03/22/new-aims-2-trials-research-on-social-behaviour-in-the-mouse-brain-and-what-it-can-tell-us-about-autism/) - [Study of screening diagnosis and early intervention in children with autism](https://www.aims-2-trials.eu/2021/04/27/study-of-screening-diagnosis-and-early-intervention-in-children-with-autism/) - [Professor Emily Jones on PsychologiCall Podcast](https://www.aims-2-trials.eu/2021/04/21/professor-emily-jones-on-psychologicall-podcast/) - [What do AIMS-2-TRIALS Autism Representatives (A-Reps) do?](https://www.aims-2-trials.eu/2021/03/17/what-do-autism-representatives-a-reps-do/) - [What services do autistic people want? What improvements are needed? Time to let policymakers know.](https://www.aims-2-trials.eu/2021/03/17/what-services-do-autistic-people-want-what-improvements-are-needed-time-to-let-policymakers-know/) - [Reduced flexible behaviour in autism is driven by less optimal learning](https://www.aims-2-trials.eu/2021/01/19/reduced-flexible-behaviour-in-autism-is-driven-by-less-optimal-learning/) - [Asymmetrical brain patterns can help identify subgroups of autistic people](https://www.aims-2-trials.eu/2020/12/02/asymmetrical-brain-patterns-can-help-identify-subgroups-of-autistic-people/) - [New analysis technique overcomes limitations in recording infant brain activity](https://www.aims-2-trials.eu/2020/11/17/new-analysis-technique-overcomes-limitations-in-recording-infant-brain-activity/) - [Exploring the genetics of how infants look at faces and how this may be linked to autism](https://www.aims-2-trials.eu/2021/01/11/exploring_genetics_of_looking/) - [UPDATE: Favourable feedback from European Medicines Agency](https://www.aims-2-trials.eu/2021/01/19/update-favourable-feedback-from-european-medicines-agency/) - [Professor Emily Jones of Birkbeck University featured on ACAMH Podcast](https://www.aims-2-trials.eu/2020/11/09/professor_emily_jones_podcast/) - [Researchers shine a light on the biology of social skills in autism](https://www.aims-2-trials.eu/2020/10/13/biology-of-social-skills/) - [Cellular memory of mother's viral infection could play a role in child's later brain development](https://www.aims-2-trials.eu/2020/09/08/cellular-memory-of-mothers-viral-infection-could-play-a-role-in-childs-later-brain-development/) - [AIMS-2-TRIALS receives favourable feedback from European Medicines Agency](https://www.aims-2-trials.eu/2020/09/08/aims-2-trials-receives-favourable-feedback-from-european-medicines-agency/) - [Autistic people have quicker and shorter eye movements than non-autistic people](https://www.aims-2-trials.eu/2020/07/16/eye_movements/) - [Autism: How gene alteration modifies social behavior](https://www.aims-2-trials.eu/2020/08/05/gene_alteration/) - [Participants wanted for online survey about services across Europe](https://www.aims-2-trials.eu/2020/03/24/eu-aims-published-more-research/) - [Other events](https://www.aims-2-trials.eu/2019/11/12/other-events/) - [Autism Representatives (A-Reps)](https://www.aims-2-trials.eu/2020/02/17/autism-representatives-a-reps/) - [Autism Representatives (A-Reps)](https://www.aims-2-trials.eu/2020/07/28/autism-representatives-a-reps-2/) - [Researcher training opportunities](https://www.aims-2-trials.eu/2020/02/17/researcher-training-opportunities/) - [Prestigious scientific awards for consortium members](https://www.aims-2-trials.eu/2020/03/24/prestigious-scientific-awards/) - [Autistic people’s social brain activity is not reduced](https://www.aims-2-trials.eu/2020/03/24/autistic-peoples-social-brain-activity-is-not-reduced/) - [Autistic people have quicker and shorter eye movements than non-autistic people](https://www.aims-2-trials.eu/2020/07/19/autistic-people-have-quicker-and-shorter-eye-movements-than-non-autistic-people/) - [COVID-19 and AIMS-2-TRIALS](https://www.aims-2-trials.eu/2020/07/20/aims-2-trials-response-to-covid-19/) - [Want to get involved?](https://www.aims-2-trials.eu/2020/02/25/want-to-get-involved/) - [Declan Murphy & Gráinne McAlonan of KCL on BBC Radio 4](https://www.aims-2-trials.eu/2020/03/20/declan-murphy-grainne-mcalonan-of-kcl-on-bbc-radio-4/) - [A new publication for Autism-Europe](https://www.aims-2-trials.eu/2020/03/24/a-new-publication-for-autism-europe-2/) - [EU-AIMS published more research than any other project in its funding call](https://www.aims-2-trials.eu/2020/03/24/eu-aims-published-more-research-2/) - [AIMS-2-TRIALS researchers at key events in Europe](https://www.aims-2-trials.eu/2019/11/13/aims-2-trials-researchers-at-key-events-in-europe/) - [Machine learning heralds a new era for autism research](https://www.aims-2-trials.eu/2020/03/20/machine-learning-heralds-a-new/) - [Eye tracking holds clues to the emergence of autism](https://www.aims-2-trials.eu/2020/03/24/eye-tracking-holds-clues/) - [Changing pupil size indicates social abilities in autism](https://www.aims-2-trials.eu/2020/03/24/changing-pupil-size/) - [Clinical Trials Network](https://www.aims-2-trials.eu/2020/03/24/clinical-trials-network/) - [Autism and the right to education in the EU](https://www.aims-2-trials.eu/2020/03/24/autism-and-the-right-to-education-in-the-eu/) - [Understanding adaptive functioning in autism](https://www.aims-2-trials.eu/2020/03/24/understanding-adaptive-functioning-in-autism/) - [Clinical trials begin at three AIMS-2-TRIALS sites](https://www.aims-2-trials.eu/2020/03/24/clinical-trials-begin/) - [Twin-study shows neurological problems are associated with autism](https://www.aims-2-trials.eu/2020/03/24/twin-study-shows-neurological-problems-are-associated-with-autism/) - [Elevated likelihood of autism and ADHD influences infants' motor development](https://www.aims-2-trials.eu/2020/06/30/elevated-likelihood-of-autism-and-adhd-influences-infants-motor-development-2/) - [Elevated likelihood of autism and ADHD influences infants' motor development](https://www.aims-2-trials.eu/2020/06/04/elevated-likelihood-of-autism-and-adhd-influences-infants-motor-development/) - [Understanding adaptive functioning in autism](https://www.aims-2-trials.eu/2020/05/07/understanding-adaptive-functioning/) - [AIMS-2-TRIALS' response to COVID-19](https://www.aims-2-trials.eu/2020/04/27/13121/) - [Autistic people’s social brain activity is not reduced](https://www.aims-2-trials.eu/2020/04/06/social-brain-activity/) - [Researcher training opportunities](https://www.aims-2-trials.eu/2020/03/24/researcher-training-opportunities-2/) - [Declan Murphy & Gráinne McAlonan of KCL on BBC Radio 4](https://www.aims-2-trials.eu/2019/10/08/listen-to-declan-murphy-and-grainne-mcalonan-of-kcl-on-bbc-radio-4/) - [A new publication for Autism-Europe](https://www.aims-2-trials.eu/2019/11/20/a-new-publication-for-autism-europe/) - [EU-AIMS published more research than any other project in its funding call](https://www.aims-2-trials.eu/2019/12/02/eu-aims-published-more-research-than-any-other-project-in-its-funding-call/) - [Prestigious scientific awards for consortium members](https://www.aims-2-trials.eu/2019/12/16/prestigious-scientific-awards-for-consortium-members/) - [Machine learning heralds a new era for autism research](https://www.aims-2-trials.eu/2019/08/20/machine-learning-heralds-a-new-era-for-autism-research/) - [Eye tracking holds clues to the emergence of autism](https://www.aims-2-trials.eu/2019/09/24/eye-tracking-holds-clues-to-the-emergence-of-autism/) - [Changing pupil size indicates social abilities in autism](https://www.aims-2-trials.eu/2019/10/16/changing-pupil-size-indicates-social-abilities-in-autism/) - [Clinical trials begin at three AIMS-2-TRIALS sites](https://www.aims-2-trials.eu/2020/02/17/clinical-trials-begin-at-three-aims-2-trials-sites/) - [Twin-study shows neurological problems are associated with autism](https://www.aims-2-trials.eu/2020/02/10/2019-twin-study/) - [Researchers reach out to the community](https://www.aims-2-trials.eu/2019/05/10/researchers-reach-out-to-the-autism-community/) - [An opportunity to influence European research](https://www.aims-2-trials.eu/2019/07/04/influence-research-across-europe/) - [Autism Representatives chosen from nearly 100 applications](https://www.aims-2-trials.eu/2019/07/03/autism-representatives-chosen-from-nearly-100-applications/) ## Pages - [Home](https://www.aims-2-trials.eu/) - Exploring the biology of autism to tailor treatments and develop new medicines - [Autism and rare genetic conditions](https://www.aims-2-trials.eu/our-research/biomarkers/rare-genetic-conditions/) - [Communication](https://www.aims-2-trials.eu/about-aims-2-trials/communication/) - [Data Sharing](https://www.aims-2-trials.eu/our-research/datasharing/) - [Data Access: Researcher](https://www.aims-2-trials.eu/our-research/data-access-researcher/) - [Data Access: Participant](https://www.aims-2-trials.eu/our-research/data-sharing-data-access-participant/) - [Development in children and adults - LEAP](https://www.aims-2-trials.eu/leap-front-page/) - [Publications](https://www.aims-2-trials.eu/news/publications/) - [Data Management & Analysis](https://www.aims-2-trials.eu/our-research/data-management-analysis/) - [Clinical Trials Network](https://www.aims-2-trials.eu/our-research/clinical-trials-network/) - We will develop a network to reduce barriers to running clinical trials in autism - [Ethics](https://www.aims-2-trials.eu/our-research/ethics/) - [Autism - Representatives](https://www.aims-2-trials.eu/about-aims-2-trials/team/autism-representatives/) - The Autism Representative Group will include autistic adults, parents and carers of autistic people from all across Europe. - [Our Working Groups](https://www.aims-2-trials.eu/our-working-groups/) - [News](https://www.aims-2-trials.eu/news/) - [Autism Policy Across Europe](https://www.aims-2-trials.eu/our-research/autism-policy-across-europe/) - [Testing New Medicines](https://www.aims-2-trials.eu/our-research/testing-new-medicines/) - [Resources](https://www.aims-2-trials.eu/autism-community/resources/) - [University of Edinburgh](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-edinburgh/) - [Our Team](https://www.aims-2-trials.eu/about-aims-2-trials/team/) - [Medicine for social difficulties](https://www.aims-2-trials.eu/our-research/testing-new-medicines/medicine-social-difficulties/) - [Biomarkers](https://www.aims-2-trials.eu/our-research/biomarkers/) - [Contacts](https://www.aims-2-trials.eu/contact/) - [Language](https://www.aims-2-trials.eu/language/) - [Project Management](https://www.aims-2-trials.eu/about-aims-2-trials/project-management/) - [Roche](https://www.aims-2-trials.eu/about-aims-2-trials/team/roche/) - [King's College London](https://www.aims-2-trials.eu/about-aims-2-trials/team/kings-college-london/) - [University of Cambridge](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-cambridge/) - [How to get involved](https://www.aims-2-trials.eu/our-research/how-to-get-involved/) - [About Us](https://www.aims-2-trials.eu/about-aims-2-trials/) - [FAQs](https://www.aims-2-trials.eu/faqs/) - Frequently asked questions. Click on each question to view our response, or scroll to the bottom to submit your own question. - [University Medical Centre Göttingen](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-medical-centre-gottingen/) - [Health Services of Madrid](https://www.aims-2-trials.eu/about-aims-2-trials/team/health-services-of-madrid/) - [Additional Resources](https://www.aims-2-trials.eu/additional-resources/) - [Policy study resources (Czech)](https://www.aims-2-trials.eu/policy-study-resources-czech/) - [French National Institute of Health and Medical Research](https://www.aims-2-trials.eu/about-aims-2-trials/team/inserm/) - [PIP Radboud, Netherlands](https://www.aims-2-trials.eu/pip-radboud/) - [European College of Neuropsychopharmacology](https://www.aims-2-trials.eu/about-aims-2-trials/team/ecnp/) - [Privacy Policy](https://www.aims-2-trials.eu/privacy-policy/) - [Copyright](https://www.aims-2-trials.eu/copyright/) - [Imprint & Disclaimer](https://www.aims-2-trials.eu/imprint-disclaimer/) - [PIP Karolinska, Sweden](https://www.aims-2-trials.eu/pip-karolinska/) - [PIP Ghent, Belgium](https://www.aims-2-trials.eu/pip-at-ghent/) - [PIP Paris](https://www.aims-2-trials.eu/pip-at-paris/) - [AIMS-2-TRIALS - Press Release](https://www.aims-2-trials.eu/aims-2-trials-press-release/) - [Our Research](https://www.aims-2-trials.eu/our-research/) - [Funding](https://www.aims-2-trials.eu/funding/) - [Autism Community](https://www.aims-2-trials.eu/autism-community/) - We will engage with the community through the ‘autism representatives‘ group including developing easy to understand videos about this project and its research. - [How You Benefit](https://www.aims-2-trials.eu/how-you-benefit/) - [AIMS-2-TRIALS - Press Release](https://www.aims-2-trials.eu/aims-2-trials-press-release-2/) - [The Preschool Brain Imaging and Behaviour Project](https://www.aims-2-trials.eu/pip/) - [Meet the PIP production team](https://www.aims-2-trials.eu/pip-meet-the-production-team/) - [PIP Kings College London](https://www.aims-2-trials.eu/pip-kcl-2/) - [Policy study resources (Spanish)](https://www.aims-2-trials.eu/policy-study-resources-spanish/) - [Newsletter 1](https://www.aims-2-trials.eu/newsletter-1/) - [Policy study resources (Slovene)](https://www.aims-2-trials.eu/policy-study-resources-slovenian/) - [Policy study resources (Français)](https://www.aims-2-trials.eu/policy-study-resources-french/) - [Policy study resources (Italian)](https://www.aims-2-trials.eu/policy-study-resources-italian/) - [Policy study resources (German)](https://www.aims-2-trials.eu/policy-study-resources-german/) - [Newsletter 2](https://www.aims-2-trials.eu/newsletter2/) - [Policy study resources (English)](https://www.aims-2-trials.eu/policy-study-resources-english/) - [Policy study resources (Polish)](https://www.aims-2-trials.eu/policy-study-resources-polish/) - [Testing medicines: GABA](https://www.aims-2-trials.eu/our-research/testing-new-medicines/gaba-studies/) - [Publications](https://www.aims-2-trials.eu/news/publications_old/) - [Our policy-related studies](https://www.aims-2-trials.eu/our-research/autism-policy-across-europe/our-policy-related-studies/) - [IMI reporting](https://www.aims-2-trials.eu/about-aims-2-trials/imireporting/) - [University of Salamanca](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-salamanca/) - [Brain activity and behaviours in early life](https://www.aims-2-trials.eu/our-research/biomarkers/brain-behaviours-early-life/) - [Clinical Network](https://www.aims-2-trials.eu/old-research/clinical-network/) - [Ethics](https://www.aims-2-trials.eu/old-research/ethics/) - [UMC Utrecht](https://www.aims-2-trials.eu/about-aims-2-trials/team/umc-utrecht/) - [Ghent University](https://www.aims-2-trials.eu/about-aims-2-trials/team/ghent-university/) - [Ulm University](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-ulm/) - [University Hospitals of Tours](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-hospitals-of-tours/) - [Technical University Munich](https://www.aims-2-trials.eu/about-aims-2-trials/team/technical-university-munich/) - [Stella Maris Foundation](https://www.aims-2-trials.eu/about-aims-2-trials/team/stella-maris-foundation/) - [University of Glasgow](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-glasgow/) - [French Alternative Energies and Atomic Energy Commission](https://www.aims-2-trials.eu/about-aims-2-trials/team/cea/) - [Stellenbosch University](https://www.aims-2-trials.eu/about-aims-2-trials/team/stellenbosch-university/) - [Uppsala University](https://www.aims-2-trials.eu/about-aims-2-trials/team/uppsala-university/) - [University of Coimbra](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-coimbra/) - [Policlínica Gipuzkoa Foundation](https://www.aims-2-trials.eu/about-aims-2-trials/team/policlinica-gipuzkoa-foundation/) - [Clinical Foundation for Biomedical Research](https://www.aims-2-trials.eu/about-aims-2-trials/team/clinical-foundation-biomedical-research/) - [Janssen](https://www.aims-2-trials.eu/about-aims-2-trials/team/janssen/) - [Novartis](https://www.aims-2-trials.eu/about-aims-2-trials/team/novartis/) - [UCB Biopharma](https://www.aims-2-trials.eu/about-aims-2-trials/team/ucb-biopharma/) - [Teva](https://www.aims-2-trials.eu/about-aims-2-trials/team/teva/) - [Autism Speaks](https://www.aims-2-trials.eu/about-aims-2-trials/team/autism-speaks/) - [Simons Foundation](https://www.aims-2-trials.eu/about-aims-2-trials/team/simons-foundation/) - [Autistica](https://www.aims-2-trials.eu/about-aims-2-trials/team/autistica/) - [Autism-Europe](https://www.aims-2-trials.eu/about-aims-2-trials/team/autism-europe/) - [University of Bristol](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-bristol/) - [Starlab](https://www.aims-2-trials.eu/about-aims-2-trials/team/starlab/) - [University of Newcastle](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-newcastle/) - [University of Groningen](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-groningen/) - [University of Oxford](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-oxford/) - [Public Hospitals of Paris](https://www.aims-2-trials.eu/about-aims-2-trials/team/public-hospitals-paris/) - [Trinity college Dublin](https://www.aims-2-trials.eu/about-aims-2-trials/team/trinity-college-dublin/) - [Birkbeck, University of London](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-london-birkbeck/) - [Noldus](https://www.aims-2-trials.eu/about-aims-2-trials/team/noldus/) - [ARTTIC](https://www.aims-2-trials.eu/about-aims-2-trials/team/arttic-2/) - [Karolinska Institute](https://www.aims-2-trials.eu/about-aims-2-trials/team/karolinska-institute/) - [DEMCON](https://www.aims-2-trials.eu/about-aims-2-trials/team/demcon/) - [Goethe University Frankfurt](https://www.aims-2-trials.eu/about-aims-2-trials/team/goethe-university-frankfurt/) - [Radboudumc](https://www.aims-2-trials.eu/about-aims-2-trials/team/radboudumc/) - [Institut Pasteur](https://www.aims-2-trials.eu/about-aims-2-trials/team/institut-pasteur/) - [University of Basel](https://www.aims-2-trials.eu/about-aims-2-trials/team/university-of-basel/) - [Central Institute of Mental Health](https://www.aims-2-trials.eu/about-aims-2-trials/team/central-institute-of-mental-health/) - [BioSci Consulting](https://www.aims-2-trials.eu/about-aims-2-trials/team/biosci-consulting/) - [Outcome Measures](https://www.aims-2-trials.eu/our-research/biomarkers/outcome-measures/) - [The influence of our early environment](https://www.aims-2-trials.eu/our-research/biomarkers/influence-early-environment/) - [Behaviour and cognition](https://www.aims-2-trials.eu/our-research/biomarkers/behaviour-and-cognition/) - [Sensory processing](https://www.aims-2-trials.eu/our-research/biomarkers/behaviour-and-cognition/sensory-processing/) - [Infection and Inflammation during Pregnancy](https://www.aims-2-trials.eu/our-research/biomarkers/infection-and-inflammation-during-pregnancy/) - [The immune system](https://www.aims-2-trials.eu/our-research/biomarkers/immune_system/) - [Repetitive behaviour & inflexibility](https://www.aims-2-trials.eu/our-research/biomarkers/behaviour-and-cognition/repetition-and-inflexibility/) - [Social interaction and rewards](https://www.aims-2-trials.eu/our-research/biomarkers/behaviour-and-cognition/social-interaction-and-rewards/) - [EU-AIMS](https://www.aims-2-trials.eu/about-aims-2-trials/eu-aims/) - [Epilepsy and Development Study](https://www.aims-2-trials.eu/our-research/biomarkers_old/epilepsy-development-study/) - [Brain Development in Babies](https://www.aims-2-trials.eu/our-research/biomarkers_old/brain-development-babies-study/) - [Testing Medicines: Tianeptine](https://www.aims-2-trials.eu/our-research/testing-new-medicines/serotonin-studies/) - [Beyond Medicines](https://www.aims-2-trials.eu/our-research/beyond-medicines/) - [Training](https://www.aims-2-trials.eu/publications/educational-center/) - [Autism Community](https://www.aims-2-trials.eu/home/autism-community/) ## Image maps - [AIMS-2-TRIALS workpackages](https://www.aims-2-trials.eu/imagemap/620/) - [Team](https://www.aims-2-trials.eu/imagemap/team/) ## Image map areas - [WP7](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-2/) - [Communication](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-3/) - [Autism Policies](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area/) - [WP6](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-7/) - [WP4](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-6/) - [WP3](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-5/) - [WP2](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-4/) - [Associated Partners](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-17/) - [(untitled image map area)](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-16/) - [(untitled image map area)](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-15/) - [(untitled image map area)](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-14/) - [(untitled image map area)](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-13/) - [Academic Leads](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-8/) - [Academia, Small-to-Medium Enterprises & Organisations](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-9/) - [Clinical Network Sites](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-10/) - [EFPIA Partners](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-11/) - [Associated Partners](https://www.aims-2-trials.eu/imagemap_area/untitled-image-map-area-12/) ## Categories - [AIMS-2-TRIALS News](https://www.aims-2-trials.eu/category/news/) - [Newsletter 1](https://www.aims-2-trials.eu/category/newsletter-1/) - [Newsletter1 Research News](https://www.aims-2-trials.eu/category/newsletter-1/newsletter1-research-news/) - [Newsletter1 Community News](https://www.aims-2-trials.eu/category/newsletter-1/newsletter1-community-news/) - [Newsletter1 Awards etc](https://www.aims-2-trials.eu/category/newsletter-1/newsletter1-awards-etc/) - [draft](https://www.aims-2-trials.eu/category/draft/) - [Newsletter 2](https://www.aims-2-trials.eu/category/newsletter-2/) - [Newsletter 2 Awards etc](https://www.aims-2-trials.eu/category/newsletter-2-awards-etc/) - [Newsletter 2 Community](https://www.aims-2-trials.eu/category/newsletter-2/newsletter-2-community/) - [Newsletter 2 - Research News](https://www.aims-2-trials.eu/category/newsletter-2/newsletter-2-research-news/) - [Newsletter 2 Events](https://www.aims-2-trials.eu/category/newsletter-2/newsletter-2-events/) - [NO CATEGORY](https://www.aims-2-trials.eu/category/no-category/) - [Newsletter 3 Research News](https://www.aims-2-trials.eu/category/newsletter-3-research-news/) - [Newsletter 3 Community](https://www.aims-2-trials.eu/category/newsletter-3-community/) - [Newsletter 3 events](https://www.aims-2-trials.eu/category/newsletter-3-events/) ## Tags - [pupils](https://www.aims-2-trials.eu/tag/pupils/) - [pupil dilation](https://www.aims-2-trials.eu/tag/pupil-dilation/) - [Birkbeck](https://www.aims-2-trials.eu/tag/birkbeck/) - [Babylab](https://www.aims-2-trials.eu/tag/babylab/) - [Emily Jones](https://www.aims-2-trials.eu/tag/emily-jones/) - [Covid-19](https://www.aims-2-trials.eu/tag/covid-19/) - [covid](https://www.aims-2-trials.eu/tag/covid/) - [autism](https://www.aims-2-trials.eu/tag/autism/) - [autistic](https://www.aims-2-trials.eu/tag/autistic/) - [services](https://www.aims-2-trials.eu/tag/services/) - [healthcare](https://www.aims-2-trials.eu/tag/healthcare/) - [health](https://www.aims-2-trials.eu/tag/health/) - [care](https://www.aims-2-trials.eu/tag/care/) - [barriers](https://www.aims-2-trials.eu/tag/barriers/) - [equality](https://www.aims-2-trials.eu/tag/equality/) - [inequality](https://www.aims-2-trials.eu/tag/inequality/)